Persistent difficulties in switching to second-line ART in sub-Saharan Africa - A systematic review and meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Madec, Yoann ^a   Leroy, Sandrine ^a   Rey Cuille, Marie Anne ^a   Huber, Florence ^b   Calmy, Alexandra ^c  

^a INSTITUT PASTEUR   (France)

^b Solthis   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; FACTUAL DATABASE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; PATIENT EDUCATION; PATIENT MONITORING; REVIEW; SYSTEMATIC REVIEW; VIRUS LOAD; ADULT; EPIDEMIOLOGY; FEMALE; INCIDENCE; MALE;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HUMANS; INCIDENCE; MALE;

EID: 84893451018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082724     Document Type: Review

References (42)

1. (2012) WHO HIV drug resistance report 2012. Available: http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html.
2. (2013) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 2013 Feb 18.
3. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, et al. (2009) The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23: 1127-1134.
4. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, et al. (2009) Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 23: 697-700.
5. van Oosterhout JJ, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, et al. (2009) Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 14: 856-861.
6. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, et al. (2009) Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 14: 1220-1225.
7. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, et al. (2011) Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 53: 1283-1290.
8. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, et al. (2011) Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised noninferiority trial. Lancet Infect Dis 11: 825-833.
9. van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W (2011) Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol 83: 1764-1769.
10. Sigaloff KC, Ramatsebe T, Viana R, de Wit TF, Wallis CL, et al. (2012) Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses 28: 171-175.
11. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, et al. (2008) Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 22: 2097-2106.
12. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, et al. (2011) Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther 16: 853-861.
13. (2009) Centre for Dissemination of reviews. Systematic Reviews: CRD's guidance for undertaking reviews in health care. Availble: http://www.york.ac. uk/inst/crd/pdf/Systematic-Reviews.pdf. Heslington, University of York. Accessed 2012 May 30.
14. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370: 1453-1457.
16. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, et al. (2007) Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 12: 83-88.
17. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A (2008) Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 22: 1305-1312.
18. Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, et al. (2009) Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 48: 115-122.
19. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, et al. (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123-131.
20. Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, et al. (2010) Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 15: 251-258.
21. Landier J, Akonde A, Pizzocolo C, Haidara I, Drabo M, et al. (2011) Switch to second-line ART in West African routine care: incidence and reasons for switching. AIDS Care 23: 75-78.
22. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, et al. (2011) Fouryear treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One 6: e18453.
23. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, et al. (2011) Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS 25: 1761-1769.
24. Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, et al. (2009) Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 23: 1867-1874.
25. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, et al. (2009) Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc 12: 38.
26. De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, et al. (2012) Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa. J Acquir Immune Defic Syndr 59: 236-244.
27. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, et al. (2012) Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 60: 428-437.
28. (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available: http://www.who.int/hiv/pub/ guidelines/arv2013/download/epub/en/index7.html. Accessed 2013 Jul 30.
29. (2010) Antiretroviral therapy for HIV infection in adults and adolescents - Recommendations for a public health approach: 2010 revision. Available: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed 2012 Nov.
30. Stadeli KM, Richman DD (2012) Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 18: 115-123.
31. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, et al. (2012) Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 54: 1660-1669.
32. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
33. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, et al. (2007) Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 45: 1492-1498.
34. Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, et al. (2011) High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc 14: 30.
35. Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, et al. (2012) Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 17: 377-386.
36. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, et al. (2012) Secondline antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis 205: 1739-1744.
37. Schoffelen AF, Wensing AM, Tempelman HA, Geelen SP, Hoepelman AI, et al. (2013) Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa. PLoS One 8: e58526.
38. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, et al. (2010) Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 11: 510-518.
39. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A (2010) Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 304: 303-312.
40. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N (2012) Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 26: 929-938.
41. (2012) UNDETECTABLE: How viral load monitoring can improve HIV treatment in developing countries. Available: http://www.msfaccess.org/sites/default/ files/MSF-assets/HIV-AIDS/Docs/MSF-ViralLoad-Report.-FINAL-Sept2012-webres.pdf. Accessed 2013 May 6. MSF Access campaign.
42. Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, et al. (2007) Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS Res Ther 4: 18.